Zeluvalimab

DB18868InvestigationalProtein Based Therapies

Zeluvalimab is under investigation in clinical trial NCT04631601 (Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (Mcrpc)).

Mechanism: Pharmacologically active on Programmed cell death protein 1
Curator reviewed
Also known as: Anti-pd-1 monoclonal antibody amg 404 · Immunoglobulin g1 (295-cysteine,300-glycine,305-cysteine), anti-(human programmed cell death 1) (human monoclonal 20c1.009 mab .gamma.1-chain), disulfide with human monoclonal 20c1.009 mab .kappa.-chain, dimer · Zeluvalimab (immunoglobulin g1-kappa, anti-(homo sapienspdcd1 (programmed cell death 1, pd-1, pd1, cd279)), monoclonal antibody)
Code names: AMG-404

Resolves to

Compound

UNIIDX474PAV6PCAS2315361-37-4

Targets

Q15116PDCD1

What you can answer from here — as of August 05, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zeluvalimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account